Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 226.06 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | BIIB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.30 | 0.13% | 226.06 | 228.33 | 225.16 | 225.41 | 225.76 | 19:49:52 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 225.11 | 226.28 | 1.17 | 0.52% | - | 4 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 23,475 | 1,978,789 | $ 226.49 | $ 448,170,004 | 1,661,352 | 215.775 - 345.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:01:52 | 8 | $ 226.28 | USD |
Biogen Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 41.70B | 184.45M | $ 4.43B | 21.62 | 8.20 | 182.48M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Biogen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIIB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 225.16 | 228.33 | 220.51 | 223.4750 | 2M | 0.9 | 0.40% |
| 1 Month | 234.86 | 242.712 | 219.7 | 229.2537 | 2M | -8.8 | -3.75% |
| 3 Months | 239 | 247.88 | 215.775 | 231.3272 | 1M | -12.94 | -5.41% |
| 6 Months | 235.04 | 247.88 | 215.775 | 230.8532 | 2M | -8.98 | -3.82% |
| 1 Year | 329.97 | 345 | 215.775 | 258.9303 | 2M | -103.91 | -31.49% |
| 3 Years | 289.89 | 388.67 | 215.775 | 284.8764 | 2M | -63.83 | -22.02% |
| 5 Years | 297.29 | 480.18 | 215.775 | 298.9946 | 2M | -71.23 | -23.96% |
Biogen Description
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. |
